PLEASE TAKE ON RECORD CLOSURE OF TRADING WINDOW DUE TO SUBMISSION OF HALF YEARLY UNAUDITED FINANCIAL STATEMENT
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aptus Pharma Limited has informed BSE that the trading window for dealing in its securities will remain closed for insiders (directors, promoters, and designated persons) starting from 15th October 2025. The window will reopen 48 hours after the conclusion of the board meeting that will approve the unaudited financial results for the half year ended 30th September 2025. This action is taken in compliance with SEBI's Prohibition of Insider Trading Regulations, 2015, and the company's internal code of conduct. The company will separately announce the date of the board meeting where these results will be approved. The letter is signed digitally by Mohini Hardikbhai Gandhi on behalf of the company.
This is a routine compliance announcement. Insiders cannot trade the stock during the closed window, which is a standard practice ahead of financial results to prevent insider trading. Retail investors should expect the half-yearly results announcement soon, which could move the stock depending on performance.